Drugs / SAMARIUM DOTMP
SAMARIUM DOTMP
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07197645 | Oct 2025 → Apr 2027 expected | bone neoplasm | Telix Pharmaceuticals (Innovations) Pty Limited | Recruiting | No outcome recorded |
| Phase 1 | NCT03612466 | Aug 2022 → Jan 2023 | bone neoplasm, osteosarcoma | Albert Einstein College of Medicine | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT06008483 | Apr 2022 → Apr 2024 | bone cancer, metastatic malignant neoplasm | QSAM Therapeutics, Inc. | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-11-14 | Telix Pharmaceuticals (Innovations) Pty Limited | Telix Announces Proposed Acquisition of QSAM Biosciences and Its Lead Therapy Candidate, CycloSam® telixpharma.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAMARIUM DOTMP | ChEMBL registry synonym — accepted as the source's own label CHEMBL4804172 ↗ |
| Known as | 153Sm-DOTMP | “A Phase 1 Pharmacokinetic, Dosimetry, Safety, and Dose Optimization Study for a Single Dose of TLX090-Tx (153SmDOTMP) to Treat Metastatic Bone Pain” NCT07197645 ↗4“This is an open-label, unblinded, multi-center, dose-finding study of 153Sm-DOTMP (CycloSam®) to identify the MTD of 153Sm- DOTMP” NCT06008483 ↗ |
| Known as | CycloSam | “This is an open-label, unblinded, multi-center, dose-finding study of 153Sm-DOTMP (CycloSam®) to identify the MTD of 153Sm- DOTMP” NCT06008483 ↗ |
| Known as | DOTMP SM-153 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4804172 ↗ |
| Known as | Samarium-153-DOTMP | “153-Sm-DOTMP (Samarium-153-DOTMP)” NCT06008483 ↗ |
| Known as | Sm-153-dotmp | ChEMBL registry synonym — accepted as the source's own label CHEMBL4804172 ↗ |
| Known as | TLX090-Tx | “A Phase 1 Pharmacokinetic, Dosimetry, Safety, and Dose Optimization Study for a Single Dose of TLX090-Tx (153SmDOTMP) to Treat Metastatic Bone Pain” NCT07197645 ↗ |
| Modality | Other / unclassified | “novel radiopharmaceutical agent” NCT03612466 ↗ |
| Route | Other | “when injected” NCT06008483 ↗ |